Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL7937455 | 1.00 | MEN1 (0.49) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| Proline SCHEMBL29191180 | 0.92 | MEN1 (0.46) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| Proline SCHEMBL29191182 | 0.92 | MEN1 (0.46) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| Proline SCHEMBL6894672 | 0.91 | BLM (0.52) | MEN1KMT2ACYP1A2THRBALOX15 | |
| Proline SCHEMBL718906 | 0.91 | BLM (0.52) | MEN1KMT2ACYP1A2THRBALOX15 | |
| Proline SCHEMBL10141181 | 0.91 | — | — | |
| Proline SCHEMBL13248912 | 0.91 | — | — | |
| D-Proline SCHEMBL21462052 | 0.91 | BLM (0.52) | MEN1KMT2ACYP1A2THRBALOX15 | |
| Proline SCHEMBL462226 | 0.91 | BLM (0.52) | MEN1KMT2ACYP1A2THRBALOX15 | |
| Proline SCHEMBL6894675 | 0.91 | BLM (0.52) | MEN1KMT2ACYP1A2THRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118021694-A | An antiaging composition containing aloe extract | 方红梅 | 2024-05-14 | — | — | CN | claimed |
| CN-118021694-A | An antiaging composition containing aloe extract | 方红梅 | 2024-05-14 | — | — | CN | disclosed |
| CN-114345919-B | Method for leaching and repairing arsenic-polluted soil by amino acid ionic liquid | 江南大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-114345919-A | Method for restoring arsenic-polluted soil by leaching amino acid ionic liquid | 江南大学 | 2022-04-15 | — | — | CN | disclosed |
| CN-107880708-B | Waterproof durable fireproof wood and preparation method thereof | 卢子强 | 2020-09-22 | — | — | CN | disclosed |
| EP-3541413-A2 | AQUEOUS PHARMACEUTICAL FORMULATIONS | Polpharma Biologics S.A. (PL) | 2019-09-25 | — | — | EP | disclosed |
| CN-105102428-B | Novel DPP-IV inhibitors | DNJ制药有限公司 | 2018-11-16 | — | — | CN | disclosed |
| WO-2018091729-A2 | AQUEOUS PHARMACEUTICAL FORMULATIONS | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2018-05-24 | — | — | WO | disclosed |
| CN-107880708-A | A kind of water-fast durable fireproof wood and preparation method thereof | 卢子强 | 2018-04-06 | — | — | CN | disclosed |
| CN-101035568-A | Combination therapy using transferrin fusion proteins comprising GLP-1 | BIOREXIS PHARMACEUTICAL CORP (US) | 2007-09-12 | — | — | CN | disclosed |
| US-6258597-B1 | CONTACTING UMBILICAL CORD BLOOD OR BONE MARROW CELLS WITH INHIBITOR OF DIPEPTIDYLPEPTIDASE TYPE IV TO INCREASE NUMBER OR DIFFERENTIATION STATE; DOES NOT USE EXOGENOUS CYTOKINE | POINT THERAPEUTICS, INC. | 2001-07-10 | — | — | US | disclosed |